TY - JOUR
T1 - In vitro efficacy of diclofenac against Listeria monocytogenes
AU - Dutta, N. K.
AU - Mazumdar, K.
AU - Baek, M. W.
AU - Kim, D. J.
AU - Na, Y. R.
AU - Park, S. H.
AU - Lee, H. K.
AU - Lee, B. H.
AU - Park, J. H.
N1 - Funding Information:
Acknowledgments This work was supported by grants provided by the Korea Research Foundation and the Brain Korea 21 project, South Korea. Transparency declarations: none to declare.
PY - 2008/4
Y1 - 2008/4
N2 - Chemotherapy is often futile in systemic listeriosis, translating to being a peril to public health. There is, thus, an imperative need for novel antilisterial compounds, possibly acting through mechanisms dissimilar to those of existing drugs. The present study describes one such agent-the non-steroidal anti-inflammatory drug (NSAID) diclofenac sodium (Dc). The National Committee for Clinical Laboratory Standards (NCCLS) minimum inhibitory concentration (MIC), mode of action, and two mechanisms of action, i.e., on bacterial DNA and membrane, have been characterized with respect to Dc. The drug showed noteworthy inhibitory action (MIC90=50 μg/ml) against Listeria strains, demonstrated cidal (minimum bactericidal concentration [MBC]=100 μg/ml) activity, inhibited listerial DNA synthesis (45.48%; incorporation of [methyl-3H] thymidine), and possessed bacterial membrane-damaging activity (37.33%; BacLight assay). Dc could be used as a lead compound for the synthesis of new, more active agents perhaps devoid of side effects. Further, quantitative structure-activity relationship (QSAR) studies will contribute to a new generation of promising adjuvants to existing antilisterial drugs.
AB - Chemotherapy is often futile in systemic listeriosis, translating to being a peril to public health. There is, thus, an imperative need for novel antilisterial compounds, possibly acting through mechanisms dissimilar to those of existing drugs. The present study describes one such agent-the non-steroidal anti-inflammatory drug (NSAID) diclofenac sodium (Dc). The National Committee for Clinical Laboratory Standards (NCCLS) minimum inhibitory concentration (MIC), mode of action, and two mechanisms of action, i.e., on bacterial DNA and membrane, have been characterized with respect to Dc. The drug showed noteworthy inhibitory action (MIC90=50 μg/ml) against Listeria strains, demonstrated cidal (minimum bactericidal concentration [MBC]=100 μg/ml) activity, inhibited listerial DNA synthesis (45.48%; incorporation of [methyl-3H] thymidine), and possessed bacterial membrane-damaging activity (37.33%; BacLight assay). Dc could be used as a lead compound for the synthesis of new, more active agents perhaps devoid of side effects. Further, quantitative structure-activity relationship (QSAR) studies will contribute to a new generation of promising adjuvants to existing antilisterial drugs.
UR - http://www.scopus.com/inward/record.url?scp=43449095017&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=43449095017&partnerID=8YFLogxK
U2 - 10.1007/s10096-007-0439-5
DO - 10.1007/s10096-007-0439-5
M3 - Article
C2 - 18188616
AN - SCOPUS:43449095017
SN - 0934-9723
VL - 27
SP - 315
EP - 319
JO - European Journal of Clinical Microbiology and Infectious Diseases
JF - European Journal of Clinical Microbiology and Infectious Diseases
IS - 4
ER -